Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XCHNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JF.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JF.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GK.1.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.1.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JE.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JE.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
JD.1.1.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JD.1.1.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XCKNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XCKNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GN.1.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GN.1.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.16.27NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.27NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.6.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.6.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FD.5.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FD.5.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DV.7.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
DV.7.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DV.7.1.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DV.7.1.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XCLNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XCLNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XCH.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XCH.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GJ.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GJ.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GJ.1.2.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GJ.1.2.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HN.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HN.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.10.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.10.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.41.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.41.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GK.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HN.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HN.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GJ.1.2.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
GJ.1.2.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.3.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.3.9NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used